Quest Partners LLC Buys 8,351 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Quest Partners LLC grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 52.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 24,219 shares of the company’s stock after acquiring an additional 8,351 shares during the period. Quest Partners LLC’s holdings in Recursion Pharmaceuticals were worth $182,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of RXRX. National Bank of Canada FI raised its position in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares during the last quarter. Wedmont Private Capital increased its stake in shares of Recursion Pharmaceuticals by 11.8% in the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after buying an additional 2,000 shares during the period. Interchange Capital Partners LLC increased its stake in shares of Recursion Pharmaceuticals by 7.3% in the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after buying an additional 2,349 shares during the period. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals in the 1st quarter valued at approximately $26,000. Finally, Victory Capital Management Inc. grew its holdings in Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after acquiring an additional 2,598 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Activity

In related news, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $7.48, for a total transaction of $374,000.00. Following the transaction, the chief executive officer now directly owns 758,738 shares of the company’s stock, valued at $5,675,360.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $7.21, for a total transaction of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $3,860,644.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total value of $374,000.00. Following the completion of the transaction, the chief executive officer now owns 758,738 shares in the company, valued at $5,675,360.24. The disclosure for this sale can be found here. Insiders sold 231,682 shares of company stock worth $1,663,867 in the last quarter. 15.75% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

RXRX has been the subject of several analyst reports. Jefferies Financial Group dropped their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. KeyCorp lowered their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Finally, Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $6.57 on Monday. The firm’s fifty day simple moving average is $7.23 and its two-hundred day simple moving average is $8.52. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $15.74. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.85 billion, a P/E ratio of -4.11 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same period in the prior year, the business earned ($0.38) EPS. The company’s revenue for the quarter was up 30.9% on a year-over-year basis. As a group, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.